Latest Tokyo Brief coverage on Cuorips Inc., tracking filings, financial news, and market signals from Japan.
TSE:4894
A fund run by JIC Venture Growth Investments bought 619,700 Cuorips shares at ¥4,841 each in a third-party allotment, paid from its own fund money, and says it is a pure investment with no significant proposals.
Japan's health ministry listed Cuorips' heart-failure therapy ReHeart at ¥53.2mn per treatment for patients who have exhausted standard drug and invasive care, using the cost-calculation pricing method under the new-technology category.
Chuikyo, Japan's insurance-pricing panel, set a ¥53.2mn reimbursement price for ReHeart, Cuorips's iPS cell-derived cardiac tissue sheet for severe heart failure, but sales cannot begin until the official listing takes effect on September 1.
Current holdings disclosed by tracked funds.
| Fund | NAV weight | Holdings as of |
|---|---|---|
| JPX Startup100 ETF | 1.16% | 29 Oct 2026 |
| TSE Growth 250 ETF | 0.81% | 29 Oct 2026 |